{"slug":"urothelial","tag":"urothelial","variants":["urothelial"],"description":"No description yet","count":8,"kinds":{"person":8},"related":[{"slug":"immunotherapy","tag":"immunotherapy","shared":4},{"slug":"adc","tag":"adc","shared":2},{"slug":"surgery","tag":"surgery","shared":2},{"slug":"trialist","tag":"trialist","shared":2},{"slug":"adjuvant","tag":"adjuvant","shared":1},{"slug":"bcg","tag":"bcg","shared":1},{"slug":"ctdna","tag":"ctdna","shared":1},{"slug":"gene-therapy","tag":"gene-therapy","shared":1},{"slug":"italy","tag":"italy","shared":1},{"slug":"neoadjuvant","tag":"neoadjuvant","shared":1}],"records":[{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","tldr":"Led EV-302, NIAGARA and IMvigor011, the trials that transformed bladder cancer from chemotherapy-only to ADC, immunotherapy and ctDNA-guided care."},{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","route":"/people/jonathan-rosenberg/","tldr":"Led the early enfortumab vedotin trials and the atezolizumab study that first brought immunotherapy to bladder cancer."},{"id":"dean-bajorin","kind":"person","name":"Dean F. Bajorin","route":"/people/dean-bajorin/","tldr":"Led CheckMate 274, which established adjuvant nivolumab after bladder cancer surgery."},{"id":"joaquim-bellmunt","kind":"person","name":"Joaquim Bellmunt","route":"/people/joaquim-bellmunt/","tldr":"Led KEYNOTE-045, the first trial to show immunotherapy beats chemotherapy in advanced bladder cancer."},{"id":"arjun-balar","kind":"person","name":"Arjun V. Balar","route":"/people/arjun-balar/","tldr":"Led KEYNOTE-052 and IMvigor210 cohort 1, establishing first-line immunotherapy for cisplatin-ineligible bladder cancer."},{"id":"ashish-kamat","kind":"person","name":"Ashish M. Kamat","route":"/people/ashish-kamat/","tldr":"Urologist who set the definitions for BCG-unresponsive bladder cancer and leads the International Bladder Cancer Group."},{"id":"andrea-necchi","kind":"person","name":"Andrea Necchi","route":"/people/andrea-necchi/","tldr":"Led PURE-01, the first neoadjuvant pembrolizumab trial in bladder cancer, and now leads bladder-preserving immunotherapy studies."},{"id":"stephen-boorjian","kind":"person","name":"Stephen A. Boorjian","route":"/people/stephen-boorjian/","tldr":"Mayo Clinic urologist who led the trial of nadofaragene firadenovec, the first gene therapy approved for bladder cancer that no longer responds to BCG."}]}